U.S. Markets open in 2 hrs 37 mins
  • S&P Futures

    4,166.75
    +20.00 (+0.48%)
     
  • Dow Futures

    32,889.00
    +132.00 (+0.40%)
     
  • Nasdaq Futures

    13,314.00
    +85.25 (+0.64%)
     
  • Russell 2000 Futures

    1,930.10
    +8.30 (+0.43%)
     
  • Crude Oil

    88.07
    -0.94 (-1.06%)
     
  • Gold

    1,795.50
    +4.30 (+0.24%)
     
  • Silver

    20.12
    +0.28 (+1.40%)
     
  • EUR/USD

    1.0190
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.8400
    0.0000 (0.00%)
     
  • Vix

    21.76
    +0.32 (+1.49%)
     
  • GBP/USD

    1.2098
    +0.0028 (+0.23%)
     
  • USD/JPY

    134.8650
    -0.1050 (-0.08%)
     
  • BTC-USD

    24,092.83
    +1,085.78 (+4.72%)
     
  • CMC Crypto 200

    560.72
    +25.50 (+4.76%)
     
  • FTSE 100

    7,476.50
    +36.76 (+0.49%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Pear Therapeutics to be Added to Russell US Index Series

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, August 02, 2022--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that it will be added to the Russell US Index Series in conjunction with the September 2022 quarterly review, effective after the US market open on Monday, September 19, 2022.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell US Index Series, go to the FTSE Russell website.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802006154/en/

Contacts

Media and Investors:
Meara Murphy
Senior Director, Corporate Communications
meara.murphy@peartherapeutics.com